EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine


76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011.

Hepatitis C virus (HCV) protease inhibitors will be the first direct-acting antivirals to emerge from the development pipeline, but polymerase inhibitors are not far behind. Mericitabine is a nucleoside analog NS5B RNA-dependent RNA polymerase inhibitor being developed by Roche/Genentech. The drug works by disabling an enzyme required to copy HCV RNA. Preclinical studies indicated that it has a high barrier to drug resistance.

Paul Pockros from the Scripps Clinic and colleagues designed the JUMP-C study to compare a response-guided therapy regimen of mericitabine plus pegylated interferon alfa-2a (Pegasys) and ribavirin versus standard therapy with pegylated interferon/ribavirin alone.

This Phase 2b trial included 166 previously untreated chronic hepatitis C patients with hard-to-treat HCV genotypes 1 or 4. About 60% were men, 78% were white, 12% were black, and the average age was 50 years. About 60% had HCV genotype 1a, 30% had 1b, and 6% had genotype 4. About one-quarter had advanced liver fibrosis or cirrhosis (Metavir stages F3-F4).

Participants were first randomly assigned to receive the mericitabine combination or standard therapy. Within the former group, those who experienced extended rapid virological response (eRVR, or HCV RNA < 15 IU/mL from week 4 to 22) received 1000 mg twice-daily mericitabine plus standard doses of pegylated interferon and ribavirin for 24 weeks. Those who did not achieve eRVR received 24 weeks of mericitabine triple therapy followed by a further 24 weeks of pegylated interferon/ribavirin alone. Everyone in the standard therapy control group received only pegylated interferon/ribavirin for 48 weeks.


"In this interim analysis, mericitabine plus [pegylated interferon/ribavirin] for 24 weeks was associated with very high rates of virological suppression (91%) and high SVR-12 (76%) in patients with eRVR (60%)," the researchers stated.

They added that mericitabine appeared to overcome the disadvantage of having an unfavorable IL28B gene pattern.

"A good safety and tolerability profile, strong antiviral potency and no evidence of resistance-related breakthrough makes mericitabine highly desirable for further study, including combinations with other [directing-acting antivirals]," they concluded.

Investigator affiliations:

Scripps Clinic Research Center, La Jolla, CA; Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL; Hawaii Medical Center, Honolulu, HI; University of Kansas Hospital Medical Center, Kansas City, KS; Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada; Ottawa Hospital, Ottowa, ON, Canada; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Infections Limited Hawaii, Honolulu, HI; Roche, Nutley, NJ; Genentech, South San Francisco, CA; Baylor College of Medicine, Houston, TX.

The JUMP-C study was funded by Roche.



P Pockros, D Jensen, N Tsai, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30-April 3. Abstract 421.